升糖素

用途

• Hypoglycemic (neuroglycopenic) crises in patients with 'insulinomas'
• Hypoglycaemia (Insulin overdose)
• Treatment of fatty liver in early lactation dairy cows older than 3.5 years
• Hypoglycemic (neuroglycopenic) crises in patients with 'insulinomas'
• Refractory hypoglycemic patients with insulinoma
• Hypoglycaemia (Insulin overdose)

給藥方式

可能的副作用

• Nausea
• Vomiting
• Hypokalemia
• Hypersensitivity reactions (very rare)
• Vomiting (main adverse reaction reported in humans)
• Anaphylaxis (rare)

注意事項與禁忌

• Pheochromocytoma
• Normoglycemia
• Pheochromocytoma (in humans)
• Insulinoma (may stimulate insulin release)
• > **Pheochromocytoma Warning**: Glucagon should usually not be used in patients with pheochromocytoma as catecholamines may be released leading to hypertension. * **Insulinoma Caution**: When used for insulinoma, it must be in a setting where blood glucose can be closely monitored. It can stimulate insulin production, potentially leading to greater rebound hypoglycemia once the drug is discontinued. * **Pregnancy/Nursing**: FDA Category B in humans. As an endogenously produced hormone, it is unlikely to cause significant risk to offspring or nursing young.

藥物相互作用

• Anticoagulants: May have their effects increased when glucagon is concurrently administered; this effect may be delayed. Monitor for bleeding and prothrombin activity.

常見問題